BioCryst to Report Second Quarter 2024 Financial Results on August 5

7/22/24 7:00:09 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BCRX alert in real time by email

RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:

John Bluth

+1 919 859 7910

[email protected]

Get the next $BCRX alert in real time by email

Recent Analyst Ratings for

$BCRX

Date	Price Target	Rating	Analyst
11/20/2023	$10.00	Overweight	JP Morgan
9/18/2023	$9.00 → $10.00	Sector Perform → Outperform	RBC Capital Mkts
8/4/2023	$11.00	Hold → Buy	Jefferies
7/13/2023	$10.00	Neutral → Buy	BofA Securities
2/22/2023	$14.00	Hold → Buy	Needham
11/2/2022	$14.00 → $16.00	In-line → Outperform	Evercore ISI
8/5/2022		Outperform → Perform	Oppenheimer
8/5/2022	$14.00	Outperform → In-line	Evercore ISI

More analyst ratings

BioCryst to Report Second Quarter 2024 Financial Results on August 5

Chat with this insight

Recent Analyst Ratings for $BCRX

$BCRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Levin Alan G bought $49,996 worth of shares (7,861 units at $6.36), increasing direct ownership by 21% to 44,951 units (SEC Form 4)

Aselage Steve bought $16,000 worth of shares (2,500 units at $6.40) (SEC Form 4)

Hutson Nancy J bought $31,900 worth of shares (5,000 units at $6.38), increasing direct ownership by 6% to 86,818 units (SEC Form 4)

$BCRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

$BCRX Financials

Live finance-specific insights

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

BioCryst to Report Third Quarter 2024 Financial Results on November 4

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

$BCRX SEC Filings

$BCRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$BCRX Market Insights

Live Market Insights

$BCRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SEC Form 10-Q filed by BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Director Milano Vincent was granted 647 shares, increasing direct ownership by 0.87% to 75,334 units (SEC Form 4)

Director Mckee Amy E sold $54,352 worth of shares (8,600 units at $6.32), decreasing direct ownership by 24% to 27,831 units (SEC Form 4)

Director Sanders Machelle sold $28,134 worth of shares (4,689 units at $6.00), decreasing direct ownership by 14% to 27,742 units (SEC Form 4)

BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients with Normal C1-Inhibitor After Beginning ORLADEYO Treatment

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

JP Morgan resumed coverage on BioCryst Pharma with a new price target

BioCryst Pharma upgraded by RBC Capital Mkts with a new price target

BioCryst Pharma upgraded by Jefferies with a new price target

$BCRX Leadership Updates

Live Leadership Updates

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

$BCRX Press Releases

Fastest customizable press release news feed in the world

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

BioCryst to Present at Upcoming Investor Conferences

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Analyst Ratings for
$BCRX

$BCRX
Insider Purchases

$BCRX
Large Ownership Changes

$BCRX
Financials

$BCRX
SEC Filings

$BCRX
Insider Trading

$BCRX
Market Insights

$BCRX
Analyst Ratings

$BCRX
Leadership Updates

$BCRX
Press Releases